Schedule 13D ownership disclosure

SpyGlass Pharma, Inc.

Common Stock, $0.00001 par value per share · CUSIP: 85220G109

Event date: 2026-02-09

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • New Enterprise Associates 17, L.P.Reported CIK 0001768564

    Shares: 7,392,301.00 · Class: 22.2%

  • NEA Partners 17, L.P.Reported CIK 0001796820

    Shares: 7,392,301.00 · Class: 22.2%

  • NEA 17 GP, LLCReported CIK 0001796821

    Shares: 7,392,301.00 · Class: 22.2%

  • New Enterprise Associates 16, L.P.Reported CIK 0001694560

    Shares: 7,392,301.00 · Class: 22.2%

  • NEA Partners 16, L.P.Reported CIK 0001712881

    Shares: 7,392,301.00 · Class: 22.2%

  • NEA 16 GP, LLCReported CIK 0001712882

    Shares: 7,392,301.00 · Class: 22.2%

  • Forest BaskettReported CIK 0001277631

    Shares: 7,392,301.00 · Class: 22.2%

  • Ali BehbahaniReported CIK 0001613867

    Shares: 7,393,823.00 · Class: 22.2%

  • Carmen ChangReported CIK 0001746342

    Shares: 7,392,301.00 · Class: 22.2%

  • Anthony A. Florence, Jr.Reported CIK 0001559827

    Shares: 7,392,301.00 · Class: 22.2%

  • Mohamad H. MakhzoumiReported CIK 0001630226

    Shares: 7,392,301.00 · Class: 22.2%

  • Edward T. MathersReported CIK 0001328625

    Shares: 6,035,038.00 · Class: 18.1%

  • Scott D. SandellReported CIK 0001237289

    Shares: 7,392,301.00 · Class: 22.2%

  • Paul WalkerReported CIK 0001553150

    Shares: 7,392,301.00 · Class: 22.2%

  • Rick YangReported CIK 0001851328

    Shares: 6,035,038.00 · Class: 18.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001072613-26-000183
Form type
SCHEDULE 13D
Filer
New Enterprise Associates 17, L.P.
CIK
CIK 1768564
Filed
Feb 13, 2026
Reporting period
Feb 09, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub